Last reviewed · How we verify

Tramadol 50

Grünenthal GmbH · Phase 3 active Small molecule

Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.

Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief. Used for Moderate acute and chronic pain.

At a glance

Generic nameTramadol 50
Also known asTramadol immediate-release capsule, Tradol (Registered Trademark)
SponsorGrünenthal GmbH
Drug classSynthetic opioid analgesic
TargetMu opioid receptor; norepinephrine transporter; serotonin transporter
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Tramadol works through dual mechanisms: it acts as a weak mu opioid receptor agonist and simultaneously inhibits the reuptake of norepinephrine and serotonin in the central nervous system. This combination of opioid and monoamine reuptake inhibition produces analgesic effects for moderate pain. The norepinephrine and serotonin reuptake inhibition component contributes significantly to its pain-relieving properties and distinguishes it from traditional opioids.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: